title: CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer.
abstract: Circulating tumor cells (CTC) have substantial promise for multipurpose biomarker studies in prostate cancer. The IMMC-38 trial conducted by de Bono and colleagues, which was published in the October 1, 2008, issue of Clinical Cancer Research, demonstrated for the first time that CTCs are the most accurate and independent predictor of overall survival in metastatic prostate cancer. Since the publication of prospective trials demonstrating prognostic utility, CTCs have been utilized for nucleic acid analyses, for protein analyses, and in intermediate endpoint studies. CTC studies are also now facilitating the analysis of intrapatient heterogeneity. See related article by de Bono et al., Clin Cancer Res 2008;14(19) October 1, 2008;6302-9.
authors.affiliation: Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom.
authors.forename: Niven
authors.initials: N
authors.lastname: Mehra
authors.affiliation: Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom.
authors.forename: Zafeiris
authors.initials: Z
authors.lastname: Zafeiriou
authors.affiliation: Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom.
authors.forename: David
authors.initials: D
authors.lastname: Lorente
authors.affiliation: Department of Medical Cell BioPhysics, University of Twente, Enschede, the Netherlands.
authors.forename: Leon W M M
authors.initials: LW
authors.lastname: Terstappen
authors.affiliation: Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. johann.de-Bono@icr.ac.uk.
authors.forename: Johann S
authors.initials: JS
authors.lastname: de Bono
mesh_terms: D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D009360:Neoplastic Cells, Circulating / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology*